Autism Spectrum Disorder
Neurodevelopmental condition with complex behavioral and communication patterns. MSC therapy targets neuroinflammation and immune dysregulation in ASD.
Autism spectrum disorder is a complex neurodevelopmental condition characterized by difficulties in social communication, restricted and repetitive behaviors, and sensory processing differences. ASD affects approximately 1 in 36 children in the United States, with a significant global prevalence across all ethnic and socioeconomic groups.
Research increasingly supports neuroinflammation and immune dysregulation as core contributors to ASD pathophysiology. Studies have documented elevated pro-inflammatory cytokines in the CSF and blood of children with ASD, activated microglia on brain imaging, and gut-brain inflammatory axis dysregulation — pointing to a biology that may be modifiable.
MSC therapy is one of the most studied regenerative interventions in ASD, with multiple clinical trials completed and published — particularly from research groups in Duke University, China, and the Middle East — showing measurable improvements in core and associated ASD symptoms.
MSCs target the neuroinflammatory environment in ASD by suppressing microglial overactivation, reducing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and promoting a Treg-mediated anti-inflammatory state. These immune regulatory effects have been proposed to reduce the sensory hypersensitivity, attention fragmentation, and behavior dysregulation associated with neuroinflammation in ASD.
Published randomized controlled trials — most prominently the Duke University cord blood studies — have demonstrated significant improvements in VABS-II socialization scores, CGI-I ratings, and vineland communication scores in treated children versus controls. Open-label trials using allogeneic MSCs have replicated these findings with good safety profiles.
True Regen evaluates ASD patients (typically children aged 2–18, with open consideration for adult patients) through a structured neurodevelopmental intake. Each case is reviewed by Regen Cord's clinical team before protocol enrollment, and standardized behavioral assessments are conducted before and at 3, 6, and 12 months post-treatment.
- Improved social communication and engagement
- Reduced repetitive and self-stimulatory behaviors
- Better language development or expressive communication
- Improved adaptive behaviors (VABS-II scores)
- Reduced sensory hypersensitivity
- Better attention, sleep, and emotional regulation
Individual results vary. All patients undergo full medical evaluation prior to treatment.
ISO/cGMP-Certified Lab
Every infusion is manufactured under pharmaceutical-grade controls. You receive a batch-specific Certificate of Analysis before treatment.
High-Dose MSC Protocol
Wharton's jelly umbilical-cord MSCs — younger, more potent, and more consistent than cells from the patient's own body.
Dedicated Coordinator
One person manages every detail of your journey — from your first inquiry through your 12-month follow-up.
Ready to take the next step?
One conversation could change everything.
Your dedicated coordinator will review your case and walk you through the entire process — with zero pressure, zero cost, and zero commitment.